RECEPTOR.AI’s Post

Recently I read an article published on BioPharm International, Volume 35, Number 11, November 2022, Pages: 10-15 by Cynthia A. Challener, PhD. I would like to put my thoughts into a discussion with like-minded people. 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬: 𝐍𝐞𝐰 𝐌𝐨𝐝𝐚𝐥𝐢𝐭𝐢𝐞𝐬, 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞, 𝐚𝐧𝐝 𝐀𝐈 𝐢𝐧 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 As highlighted in the recent article by the Author, the increasing molecular diversity of new drug modalities such as 𝐦𝐑𝐍𝐀, 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, 𝐚𝐧𝐝 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 is driving a need for innovation in 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬. The complexity of these therapies, from process automation challenges to raw material supply chain constraints, presents exciting opportunities for innovation. With 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 becoming a key focus, it’s clear that new technologies, including 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐦𝐨𝐝𝐞𝐥𝐥𝐢𝐧𝐠 𝐚𝐧𝐝 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧, are critical to improving the efficiency of biologics development. How can we ensure that AI tools, 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 (𝐏𝐀𝐓), and digital simulations evolve to keep pace with the rapid development of these new modalities? I'd love to hear your thoughts on: 1. How AI can streamline 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬. 2. The role of 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 in shaping future development. 3. Ways to tackle supply chain and process complexity for 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. Let's discuss how we can continue to innovate in biologics to deliver safe, effective therapies to patients faster. #Biologics #NewModalities #AIinHealthcare #PersonalisedMedicine #ProcessDevelopment #BiotechInnovation #Pharma

Multiplex assays are crucial for their ability to analyze multiple analytes simultaneously, revolutionizing diagnostics & research by providing comprehensive data from minimal sample volumes. Our latest blog, ‘𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞𝐱 𝐀𝐬𝐬𝐚𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐋𝐚𝐭𝐞𝐬𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐚𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬,’ delves into the market's burgeoning growth, driven by technological advancements. Check Here: https://lnkd.in/dr7i_dz8 It also explores the rising applications of multiplex assays in myriad spheres such as, drug discovery, biomarker identification, and clinical diagnostics. So, take a moment to read the blog and gain a deeper understanding of the core dynamics shaping this market. Also, don’t forget to like, share, and follow us for more updates and discussions on such cutting-edge topics! What do you think is the most promising application of multiplex assays that could transform healthcare diagnostics? Share your thoughts in the comments below! . . . abcam BD Bio-Rad Laboratories Bio-Techne #multiplexassay #healthcare #diagnosticdevices #biomarker #multiplextesting #clinicaldiagnostics #marketresearch #inkwoodresearch

Quantiphi Invests in Transcell to Advance AI-Driven Drug Discovery - HIT Consultant #QuantiphiInvestment: Quantiphi, a healthcare IT company, has made an investment in Transcell to enhance AI-driven drug discovery. This partnership aims to revolutionize the pharmaceutical industry by leveraging advanced technologies. #AIinDrugDiscovery: The collaboration between Quantiphi and Transcell will focus on utilizing artificial intelligence to streamline the drug discovery process. This innovative approach has the potential to accelerate the development of new medications and treatments. #Benefits of AI: By incorporating AI into drug discovery, researchers can analyze vast amounts of data more efficiently and accurately. This can lead to the identification of novel drug targets and the development of personalized therapies for patients. #TranscellTechnology: Transcell's cutting-edge technology will play a crucial role in this partnership ai.mediformatica.com #investment #technology #biotech #drugdiscovery #strategic #this #aifirst #applications #busine #collaboration #digital #improvingpatientoutcomes #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3X2mfsZ)

AI in Drug Discovery Market | Grows at CAGR of 40.2% by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/d6pUHAbz The global AI in drug discovery market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $4.9 billion by 2028, growing at a CAGR of 40.2% from 2023 to 2028. NVIDIA Exscientia Google BenevolentAI Recursion Insilico Medicine Schrödinger Microsoft Atomwise Illumina NuMedii XtalPi Inc. Iktos Arterys (Acquired by Tempus Labs) Deep Genomics Verge Genomics BenchSci insitro Valo Health BPGbio Inc. Predictive Oncology Labcorp IQVIA Tencent Celsius Therapeutics CytoReason Owkin Cloud Pharmaceuticals, Inc. Evaxion Biotech A/S Standigm BioAge Labs Envisagenics ARIAD Pharmaceuticals, Inc.

AI in Drug Discovery Market Size to Hit US$ $4.9 billion by 2028 ✅ 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 & 𝐆𝐞𝐭 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞:- https://lnkd.in/dddNRqR2 The global AI in drug discovery market, valued at $0.9 billion in 2023, is projected to grow to $4.9 billion by 2028, with a CAGR of 40.2%. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 NVIDIA Exscientia Google BenevolentAI Recursion Insilico Medicine Schrödinger Microsoft Atomwise Illumina NuMedii XtalPi Inc. iktos Arterys (Acquired by Tempus Labs) Deep Genomics Verge Genomics BenchSci insitro Valo Health BPGbio, Inc. Predictive Oncology Labcorp IQVIA IGE/Affinity Media (acq. Tencent Holdings Ltd.) Celsius Therapeutics CytoReason Owkin Cloud Pharmaceuticals, Inc. Evaxion Biotech A/S Standigm BioAge Labs Envisagenics ARIAD Pharmaceuticals, Inc.

AI in Drug Discovery Market Size to Hit US$ $4.9 billion by 2028 ✅ 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 & 𝐆𝐞𝐭 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞:- https://lnkd.in/dddNRqR2 The global AI in drug discovery market, valued at $0.9 billion in 2023, is projected to grow to $4.9 billion by 2028, with a CAGR of 40.2%. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 NVIDIA Exscientia Google BenevolentAI Recursion Insilico Medicine Schrödinger Microsoft Atomwise Illumina NuMedii XtalPi Inc. iktos Arterys (Acquired by Tempus Labs) Deep Genomics Verge Genomics BenchSci insitro Valo Health BPGbio, Inc. Predictive Oncology Labcorp IQVIA IGE/Affinity Media (acq. Tencent Holdings Ltd.) Celsius Therapeutics CytoReason Owkin Cloud Pharmaceuticals, Inc. Evaxion Biotech A/S Standigm BioAge Labs Envisagenics ARIAD Pharmaceuticals, Inc.

Traditional drug discovery methods are often inefficient and costly, but Discovery-seq is changing the game by leveraging high-throughput sequencing to more effectively identify and validate drug targets. Read our latest blog to learn why this innovation can lead to better and more drug targets.

AI in Drug Discovery Market Size to Hit $4.9 Billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/d7QeQFQv The size of global AI in drug discovery market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $4.9 billion by 2028, growing at a CAGR of 40.2% from 2023 to 2028 Companies From the Market NVIDIA Exscientia Google BenevolentAI Recursion Insilico Medicine Schrödinger Microsoft Atomwise Illumina NuMedii XtalPi Inc. iktos Arterys (Acquired by Tempus Labs) Deep Genomics Verge Genomics BenchSci insitro Valo Health BPGbio, Inc. Predictive Oncology Labcorp IQVIA Celsius Therapeutics CytoReason Owkin Cloud Pharmaceuticals, Inc. Evaxion Biotech A/S Standigm BioAge Labs Envisagenics ARIAD Pharmaceuticals, Inc.

✴ The pharmaceutical industry is evolving rapidly, driven by cutting-edge technologies and innovative therapies. Here are five key trends shaping its future: 🔹 Personalized Medicine: Tailor-made treatments based on genetic data improve outcomes and reduce side effects. 🔹 AI & Big Data: Revolutionizing drug discovery, AI reduces costs and enhances precision in therapy identification. 🔹 Digital Health: Wearables enable real-time tracking of treatment efficacy and patient well-being. 🔹 Biologics & Gene Therapies: Advanced therapies offer hope for previously untreatable conditions. 🔹 Sustainability: Pharma focuses on eco-friendly innovations, addressing global health challenges sustainably. Let's work together to make healthcare more personalized, accessible, and sustainable for a healthier future. #FutureOfPharma #PharmaInnovation #AIinHealthcare #PersonalizedMedicine #Biotech #DigitalHealth

The partnership between Molecular Devices and Anivance.AI empowers users with cutting-edge image-based drug screening on organ-on-chip platforms, offering advanced solutions for future trends in drug discovery.